| Dr Emily Ann Roblin, PT, DPT | |
|
894 Loop 337 Ste C, New Braunfels, TX 78130-3546 | |
| (830) 609-2000 | |
| Not Available |
| Full Name | Dr Emily Ann Roblin |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 5 Years |
| Location | 894 Loop 337 Ste C, New Braunfels, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164077368 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 1320815 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mission Rehabilitation And Sports Medicine Limited Partnership | 6709943160 | 15 |
News Archive
The team of researchers used genome-wide association techniques and found that several genetic variants associated with adult obesity are also active in childhood obesity, according to Struan Grant of the Children's Hospital of Philadelphia and colleagues. The analysis found two new genetic variants that had not been previously associated with obesity, Grant and colleagues reported online in Nature Genetics. The findings show that "there is indeed a genetic signature of childhood obesity," Grant said. "It's not purely lifestyle."
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
According to the National Center for Chronic Disease Prevention and Health Promotion, 46 million Americans have arthritis. Many of these people take over-the-counter anti-inflammatory medications that block production of certain molecules, known as bioactive lipids, to reduce pain and swelling. Yet, the role of these lipids is not yet understood completely, and medications may have adverse side effects.
Some doctors yell and scream. Some throw surgical instruments. They berate nurses, other health care workers and even patients with snide remarks and insults.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
› Verified 2 days ago
| Provider Name | Mission Rehabilitation And Sports Medicine Limited Partnership |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1053559443 PECOS PAC ID: 6709943160 Enrollment ID: O20090330000478 |
News Archive
The team of researchers used genome-wide association techniques and found that several genetic variants associated with adult obesity are also active in childhood obesity, according to Struan Grant of the Children's Hospital of Philadelphia and colleagues. The analysis found two new genetic variants that had not been previously associated with obesity, Grant and colleagues reported online in Nature Genetics. The findings show that "there is indeed a genetic signature of childhood obesity," Grant said. "It's not purely lifestyle."
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
According to the National Center for Chronic Disease Prevention and Health Promotion, 46 million Americans have arthritis. Many of these people take over-the-counter anti-inflammatory medications that block production of certain molecules, known as bioactive lipids, to reduce pain and swelling. Yet, the role of these lipids is not yet understood completely, and medications may have adverse side effects.
Some doctors yell and scream. Some throw surgical instruments. They berate nurses, other health care workers and even patients with snide remarks and insults.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Emily Ann Roblin, PT, DPT 894 Loop 337 Ste C, New Braunfels, TX 78130-3546 Ph: (830) 609-2000 | Dr Emily Ann Roblin, PT, DPT 894 Loop 337 Ste C, New Braunfels, TX 78130-3546 Ph: (830) 609-2000 |
News Archive
The team of researchers used genome-wide association techniques and found that several genetic variants associated with adult obesity are also active in childhood obesity, according to Struan Grant of the Children's Hospital of Philadelphia and colleagues. The analysis found two new genetic variants that had not been previously associated with obesity, Grant and colleagues reported online in Nature Genetics. The findings show that "there is indeed a genetic signature of childhood obesity," Grant said. "It's not purely lifestyle."
For the first time, researchers are using proteomics to examine proteins and peptides in saliva in order to accurately detect exposure to Zika virus.
According to the National Center for Chronic Disease Prevention and Health Promotion, 46 million Americans have arthritis. Many of these people take over-the-counter anti-inflammatory medications that block production of certain molecules, known as bioactive lipids, to reduce pain and swelling. Yet, the role of these lipids is not yet understood completely, and medications may have adverse side effects.
Some doctors yell and scream. Some throw surgical instruments. They berate nurses, other health care workers and even patients with snide remarks and insults.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
› Verified 2 days ago
Nancy Patten, Physical Therapist Medicare: Medicare Enrolled Practice Location: 2166 Ranch Loop Dr, New Braunfels, TX 78132 Phone: 830-237-5527 | |
Gruene Therapy Services, Pllc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1067 Fm 306 Ste 608, New Braunfels, TX 78130 Phone: 737-344-0245 | |
Mrs. Katie Elizabeth Halliburton, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1528 E Common St, Ste 23, New Braunfels, TX 78130 Phone: 830-620-4922 Fax: 830-625-1194 | |
Jessica Mendoza, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 272 Fm 306 Ste 122, New Braunfels, TX 78130 Phone: 830-500-5300 Fax: 830-500-5350 | |
Mr. Christopher M Mueller, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 821 Us Highway 81 W, New Braunfels, TX 78130 Phone: 210-912-7537 | |
Aimee Moreau Anthony, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1324 Common St, Suite 307, New Braunfels, TX 78130 Phone: 830-625-7310 | |
Mr. Francisco Yap Jr., PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2056 Sundance Pkwy Apt 7207, New Braunfels, TX 78130 Phone: 716-335-4998 |